 PLANEGGMUNICH, GERMANY ACCESSWIRE October 11, 2021 MorphoSys AG FSE:MORNASDAQ:MOR announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food and Drug Administration FDA for gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, for the treatment of people living with Alzheimers disease AD. This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of AD, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies. 